Susquehanna Fundamental Investments, LLC Clovis Oncology, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $148,701 - $403,617	-141,620 Reduced 55.12%	115,299 $137,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $61,896 - $135,911	-43,284 Reduced 14.42%	256,919 $519,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $311,307 - $548,823	115,299 Added 62.36%	300,203 $814,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $750,710 - $1.07 Million	184,904 New	184,904 $825,000
Q2 2021 Aug 11, 2021	SELL	$5.02 - $7.05 $580,452 - $815,177	-115,628 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $556,170 - $1.2 Million	115,628 New	115,628 $812,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $121,009 - $187,813	-29,300 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $166,717 - $283,917	29,300 New	29,300 $198,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.